Alnylam Pharmaceuticals, Inc. (LON:0HD2)

Market Cap	32.55B +23.1%
Revenue (ttm)	2.39B +53.2%
Net Income	32.41M
EPS	0.25
Shares Out	n/a
PE Ratio	1,004.48
Forward PE	34.02
Dividend	n/a
Ex-Dividend Date	n/a

Volume	317
Average Volume	355
Open	356.42
Previous Close	346.23
Day's Range	337.03 - 358.10
52-Week Range	209.75 - 500.21
Beta	0.32
RSI	31.01
Earnings Date	Feb 12, 2026

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc. discovers, develops, and commercializes therapeutics based on ribonucleic acid interference. It offers ONPATTRO and AMVUTTRA for hereditary transthyretin-mediated amyloidosis; GIVLAARI for acute hepatic porphyria; OXLUMO for primary hyperoxaluria type 1; and Leqvio for hypercholesterolemia. It also develops vutrisiran, which is in phase III clinical trial for transthyretin amyloidosis (ATTR) with cardiomyopathy; Nucresiran that is in phase I clinical trial for ATTR amyloidosis; Fitusiran, which is in phase III clin...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 2002
• Employees: 2,230
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0HD2

Financial Performance

In 2024, Alnylam Pharmaceuticals's revenue was $2.25 billion, an increase of 22.97% compared to the previous year's $1.83 billion. Losses were -$278.16 million, -36.82% less than in 2023.

Financial numbers in USD